gemcabene has been researched along with docetaxel anhydrous in 1 studies
| Studies (gemcabene) | Trials (gemcabene) | Recent Studies (post-2010) (gemcabene) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 18 | 3 | 9 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | gemcabene (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goodman, MD; Huber, K; McPartland, S; Saif, MW | 1 |
1 other study(ies) available for gemcabene and docetaxel anhydrous
| Article | Year |
|---|---|
New developments in the management of borderline resectable pancreatic cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Caproates; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Taxoids; Treatment Outcome | 2013 |